|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
intramuscular injection
|
|
gptkbp:alsoKnownAs
|
gptkb:Johnson_&_Johnson_COVID-19_Vaccine
gptkb:Janssen_COVID-19_Vaccine
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
2021-02-27
|
|
gptkbp:category
|
gptkb:COVID-19_vaccines
Viral vector vaccines
Johnson & Johnson products
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:contains
|
recombinant, replication-incompetent adenovirus type 26 expressing the SARS-CoV-2 spike protein
|
|
gptkbp:countryOfOrigin
|
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:doseRegimen
|
single dose
|
|
gptkbp:efficacyAgainstSevereCOVID19
|
85%
|
|
gptkbp:emergencyServices
|
gptkb:European_Union
gptkb:United_States
gptkb:World_Health_Organization
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ad26.COV2.S
|
|
gptkbp:parentCompany
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
injection site pain
thrombosis with thrombocytopenia syndrome
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:vectorFor
|
gptkb:adenovirus_serotype_26
|
|
gptkbp:WHOEmergencyUseListing
|
2021-03-12
|
|
gptkbp:withdrawn
|
2023-05-07
|
|
gptkbp:withdrawnOrSuspendedIn
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:bfsParent
|
gptkb:Janssen_COVID-19_vaccine
|
|
gptkbp:bfsLayer
|
6
|